Apitope is a European biotech company focused on the discovery and development of revolutionary disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, FVIII intolerance and uveitis.
Apitope’s mission is to develop novel therapeutics that directly target the underlying cause of allergy and autoimmune disease.
Our approach is unique in restoring the natural balance of the immune system with highly selective peptides that exert their effects directly.
The Apitope approach does NOT broadly suppress the immune system, allowing patients to enjoy a normal quality of life without the risk of secondary infection and further complications.
Apitope peptide therapies are identified using our patented discovery platform. This has allowed us to build an impressive pipeline of candidate therapeutics, the most advanced of which is currently undergoing early clinical trials in patients as a treatment for multiple sclerosis.
We have forged partnerships with investors and pharmaceutical companies worldwide pushing forward the development of potentially life changing therapies as quickly and efficiently as possible.